Article info
Poster Presentations
Rheumatoid arthritis - other biologic treatment
SAT0205 Long-term drug survival and causes of discontinuation of subcutaneous abatacept in rheumatoid arthritis: 32-month results from a prospective cohort study
Citation
SAT0205 Long-term drug survival and causes of discontinuation of subcutaneous abatacept in rheumatoid arthritis: 32-month results from a prospective cohort study
Publication history
- First published June 15, 2017.
Online issue publication
January 09, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions